Lonza, announced that it has acquired Synaffix for the development of Antibody-Drug Conjugates (ADCs).
The acquisition of Synaffix by Lonza will enable the integration of Lonza's development and manufacturing capabilities with Synaffix's ADC technology platform. This combined offering will provide customers and licensees with a comprehensive service that covers the entire process of discovering, developing, scaling up, and commercialising novel and differentiated ADCs.
This integration aims to offer an efficient and seamless pathway for bringing innovative ADC therapies to the market, ultimately benefiting patients in need of advanced treatment options.
Lonza's acquisition of Synaffix highlights the strategic importance of bioconjugates within its portfolio. By bringing Synaffix into the fold, Lonza expands its offering in the rapidly growing bioconjugate market and strengthens overall value proposition for clinical customers. The combined expertise and capabilities of Lonza and Synaffix enables to position as leaders in the industry, capable of providing comprehensive support for both clinical development and commercial manufacturing needs.
